• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a novel lactic acid bacterial strain and a composition containing the same. In addition, the present invention relates to an antibacterial composition, a cosmetic composition, and functional food, which contain the lactic acid bacterial strain and a culture medium thereof.
    公开号:EP3708649A1
    申请号:EP18875062.4
    申请日:2018-06-21
    公开日:2020-09-16
    发明作者:Jong Seung Lee
    申请人:Amtixbio Co Ltd；
    IPC主号:A01N63-00
    专利说明:
    [0001] The present invention relates to a novel lactic acid bacteria strain and a composition comprising the same. In addition, the present invention relates to an antibacterial composition, a cosmetic composition, and a functional food comprising the lactic acid bacteria strain or culture supernatant thereof. BACKGROUND OF THE INVENTION
    [0002] Lactic acid bacteria decompose carbohydrates, such as, glucose or lactose, and produce lactic acids using the carbohydrates decomposition products. Currently about 300 to 400 lactic acid bacteria are known. Various kinds of lactic acid bacteria are widely distributed in digestive tracts of humans or animals, fermented foods, for example, milk, yogurt, cheese, kimchi, etc., plants and soil, and the like. The representative lactic acid bacteria include Lactobacillus, Lactococcus, Streptococcus, Leuconostoc, Pediococcus, and Bifidobacterium.
    [0003] Organic acids, such as, lactic acids and acetic acids produced by lactic acid bacteria exhibit excellent antibacterial activity against harmful bacteria grown in neutral and basic environments, and researches have been conducted to use lactic acid bacteria as preservatives for food, etc. using the antimicrobial properties. In addition, the bacteriocin produced by the lactic acid bacteria is a peptide or a protein-based antibacterial material, and the strains producing these bacteriocins exhibit strong antibacterial activity mainly against the strains which are phylogenetically similar to themselves. Accordingly, attempts have been made to isolate a peptide or a protein having antibacterial activities from lactic acid bacteria, identify characteristics thereof, and develop the same as an antibacterial material or an anti-inflammatory therapeutic agent. In particular, the bacteriocin has an advantage in developing the same as an antibacterial material or an anti-inflammatory therapeutic agent in that the bacteriocin is composed of a peptide or a protein and thus is easily decomposed in a body and thus there is no problem of human toxicity. For example, Nisin has been developed and widely used as a bacteriocin having a broad range of antimicrobial activity.
    [0004] The tight junction of intestinal epithelial cells is important to maintain homeostasis of the intestinal immune functions. Claudin-4, Zo-1 and Occludin-4 are known as proteins constituting the tight junction, and, in particular, Claudin-1, Zo-1 and Occludin-4 are involved in the tight junctions of skin epithelial cells. It has been found that the function of tight junction is damaged in allergy caused by food, enteritis, autoimmune diseases, and Celiac disease and inflammatory bowel diseases, etc. (Fasano, A., Pathological and therapeutical implications of macromolecule passage through the tight junction. In Tight Junctions, CRC Press, Inc., Boca Raton, Fla. 697-722 (2001)). The tight junction acts as a barrier against the macromolecules entering into a human body. In a healthy state, only a small amount of immunologically active antigens can be introduced into the body through the barrier of the intestinal mucosa. If the tight junction system is damaged by radiation, chemotherapy or toxin or the like, a detrimental immune response leading to harmful autoimmune diseases and food allergy occurs. In the normal intestine, the intestinal immune response is adjusted to maintain the homeostasis of the intestine. The Celiac disease (CD) is a kind of chronic autoimmune disease, and gluten, which is a major protein fraction of wheat, is known as a factor leading to this disease. The digested gluten or derivatives thereof is deamidated by tissue transglutaminase (tTG) after passing through the small intestine epithelial cell wall and induces harmful T cell-mediated immune response while being involved in class II MHC molecules. When the tight junction system is damaged by such as the CD, the paracellular leak (leaky gut) and a response to the environmental antigens occur.
    [0005] The inflammatory bowel disease (IBD) refers to an undesirable immune response developing in the intestine. Two types of IBD have been known: Crohn's disease and ulcerative colitis (UC). These two types of inflammatory bowel disease show an abnormal profile of T cell-mediated immunity. In patients with Crohn's disease, a strong Th1 response is induced, and in the colon of a UC patient, the Th2 response is raised. In the IBD, the barrier function of the intestine is destroyed. For example, the Crohn's disease is associated with increased permeability of the intestinal barrier (Oshitani, et al. Int. J Mol. Med. 15: 407-10; Ye Arch, et al, Am J Physiol.-Gastro Arch. And Cover Physiol. 290: 496-504, Wilmington, Del. et al. Clin. Exp. Immunol. 142: 275-284).
    [0006] A tight junction is a barrier that is present in epithelial cells and that secures adjacent cell membrane sides to each other and prevents the flow of water and bodily fluids through the cell's side space. As the stratum corneum is damaged, the concentration of calcium ions is reduced together with the loss of a body fluid existing between the stratum corneum and the granular layer, so that the tight junctions of the upper portion of the granular layer is opened, and the dendrites of the Langerhans cells located just below the tight junctions are raised above the tight functions. The protein antigens with large molecular weight passing through the damaged stratum corneum are collected and recognized by the dendrite of Langerhans cell and transferred to local lymph nodes, and the serine-family proteases of the protein antigens activate PAR-2 present in the keratinocyte membrane. On the other hand, the bacteria that penetrate the stratum corneum activate the toll-like receptor (TLR). The keratinocytes secret various chemokines and cytokines, such as, TNF-α, IL-1 and thymic stromal lymphopoietin (TSLP), etc. to promote the onset of atopic dermatitis and exacerbate the disease. In addition, the expression of the tight junction proteins is significantly reduced in the skin of the atopic dermatitis patient comparing to the normal person. Recently, the Claudin-1 gene (CDN1) mutation has been reported among the atopic dermatitis patients and it is reported that the reduction of Claudin-1 in the tight junctions is one of the reasons for herpes virus infection (De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011;127:773p786e7.9).
    [0007] We, inventors, have strived to isolate lactic acid bacteria strains having excellent antibacterial activity as well as antifungal activity, and as a result, confirmed that lactic acid bacteria strains isolated from Korean traditional foods, such as, fermented soybean paste or the like exhibit wide range of antibacterial activities and outstanding antifungal activities. We confirmed that the identified novel lactic acid bacteria belong to the Pediococcus pentosaceus and named it as Pediococcus pentosaceus AB160011. DETAILED DESCRIPTION OF THE INVENTION TECHNICAL PROBLEM TO BE SOLVED
    [0008] The purpose of the present invention is to provide a novel lactic acid bacteria strain having antibacterial and antifungal activities.
    [0009] In addition, the present invention provides a novel lactic acid bacteria strain which increases the expression of proteins constituting tight junctions.
    [0010] In addition, the objective of the present invention is to provide a functional food for improving inflammatory bowel disease and immune diseases, comprising the lactic acid bacteria strains of the present invention.
    [0011] In addition, the objective of the present invention is to provide an antibacterial and antifungal composition comprising the lactic acid bacteria strains above or cell-free culture supernatant of the lactic acid bacteria strains of the present invention.
    [0012] In addition, the present invention provides a cosmetic composition comprising the lactic acid bacteria strains above or cell-free culture supernatant of the lactic acid bacteria strains of the present invention. TECHENICAL SOLUTION
    [0013] To achieve the purpose, the present invention provides a novel Pediococcus pentosaceus AB 160011 strain. EFFECT OF THE INVENTION
    [0014] The Pediococcus pentosaceus AB 160011, according to the present invention, has excellent acid resistance and bile resistance, and exhibits antibacterial and antifungal activities. In addition, it has been found that the strain of the present invention and the culture supernatant thereof significantly increase the expression of the proteins constituting the tight junctions of the epithelial cells of the skin and the intestine, and has been shown to have an effect of enhancing skin moisturization according to clinical trials. In addition, the novel lactic acid bacteria strain culture supernatant has anti-inflammatory and antioxidant effects. BRIEF DESCRIPTION OF THE DRAWINGS
    [0015] FIG.1 is a microscopic picture of Pediococcus pentosaceus AB 160011 strain of the present invention. FIG.2 is a phylogenetic tree showing the molecular biological associations of the strain of the present invention. FIG.3 is a graph showing the DNA sequence of the strain of the present invention. FIG.4 is a graph showing a growth curve of the strain of the present invention. FIG.5 is a graph showing pH changes according to the growth time of the strain of the present invention. FIG.6 shows the results obtained by inducing the expression of Claudin-4 by the strain of the present invention in CaCo2 cells. FIG.7 shows the results obtained by inducing the expression of Claudin-1 by the culture supernatant of the strain of the present invention in HaCaT cells. FIG.8 shows selective inhibitory activities against intestinal pathogens and beneficial bacteria of the strain of the present invention. FIG.9 is a result of measuring the amount of change in Nitric Oxide, an inflammatory response indicator, by the culture supernatant of the strain of the present invention. FIG.10 is a result of measuring the amount of change in Nitric oxide, an inflammatory response indicator, by the strain of the present invention. FIG.11 shows the anti-inflammatory effect by the culture supernatant of the strain of the present invention. FIG.12 shows the antioxidant effects by the culture supernatant of the strain of the present invention. FIG.13 shows a skin irritation replacement test by the culture supernatant of the strain of the present invention. FIG.14 shows the skin moisture improvement effects by the culture supernatant of the strain of the present invention.BEST MODE
    [0016] The present invention will now be described in more detail with reference to the following examples. The following examples are merely illustrative of the present invention, and it is to be understood that the scope of the invention is not limited to the following examples. Isolation and identification, and examples of manufacture (1) Isolation of lactic acid bacteria
    [0017] Various kinds of lactic acid bacteria were isolated from fermented products including kimchi, soy sauce, and soybean paste prepared in Korea in order to screen lactic acid bacteria strains having antibacterial and antifungal activities, and cultured in a MRS (Difco 288110) solid medium containing 2% agar using a 10-fold dilution method to obtain the colonies. The resulting colonies were classified according to size, color, and characteristics, and then streaked onto another MRS medium to separate a total of 1,785 lactic acid bacteria of the target strains. Each colony of the isolated lactic acid bacteria was streaked again onto MRS agar plates and incubated at 37°C for 24 hours. The isolated lactic acid bacteria were inoculated into the sterilized MRS broth and incubated at 37°C for 24 hours, followed by the addition of 20%(v/v) glycerol and stored in a ultra-low temperature freezer at -80°C. (2) Strain Identification Morphology analysis
    [0018] In order to identify the strains, the morphology of the colonies was observed under a microscope after being cultured in MRS plate media. The colonies' morphology is shown in Table 1, and FIG.1 is a microscopic picture of the strain of the present invention. [Table 1] Pediococcus pentosaceus AB160011 phenotype circular size 0.8 ∼ 1.0 mm color white opacity opaque cell surface morphology protrusion surface smoothness Identification by 16S rRNA
    [0019] The novel strain of the present invention was found to have a 16S rRNA sequence as shown in SEQ ID NO: 1. Based on this, the isolated strain was found to have high similarity to Pediococcus pentosaceus AJ3053 and named Pediococcus pentosaceus AB160011, and deposited with deposition accession no. KCCM11954P at Korean Culture Center of Microorganisms (KCCM) on December 7, 2016. Identification by DNA sequence analysis
    [0020] It was confirmed that the novel strain of the present invention has 98.97% homology with Pediococcus pentosaceus (ATCC25745 ATP), according to DNA sequence analysis (Gepard, Nucleotide sequences Dot plot) (see FIG.3). Cell culture property
    [0021] The novel lactic acid bacteria strains of the present invention were inoculated into a sterile MRS broth medium and incubated at 37°C to observe changes in turbidity (Ultrospec2100pro,
    [0022] OD625 nm) and acidity (Orion star A211, pH). FIGS.4 and 5 show the growth curve and acidity change of the strain of the present invention. Cultivation of lactic acid bacteria strains and freeze drying of the cell-free culture supernatant
    [0023] The composition of the medium for culturing lactic acid bacteria is shown in Table 2, and the manufacturing process is largely classified into as follows: seed culture, main culture, separation of strains and cell-free culture supernatant, and freeze-drying. The seed culture refers to the process of culturing the strains to a volume of 10% of the final culture volume, depending on the size of the target final culture volume. After the seed culture is completed, the obtained seed culture solution including the strains is inoculated into another sterilized culture medium having larger volume and cultured, which is main culture. After the completion of the said main culture, the lactic acid bacteria and the culture supernatant are separated by centrifugation and/or using ceramic filter to obtain cell-free strain culture supernatant. The separated lactic acid bacteria and the cell-free culture supernatant are freeze-dried through a pre-freezing process and processed into a final powder form stored at -20°C for the following use. [Table 2] Concentration (g/L) Glucose dextrose 10 MgSO4 0.1 Yeast extract 5 Whey 2.5 Sodium acetate 5 Trisodium citrate 2 K2HPO4 2 MnSO4 0.05 BEST MODE FOR INVENTION Example Example 1: Culture of pathogens
    [0024] In order to select lactic acid bacteria inhibiting the growth of pathogenic bacteria, the following bacteria were obtained from KCCM and cultured in the solid media presented in Table 3 below. Bacteria: Staphylococcus aureus (KCCM11335), Escherichia coli (KCCM11234), Bacillus cereus (KCCM40935), Staphylococcus epidermidis (KCCM40416), Pseudomonas (KCCM11321), Propionibacterium aeruginosa (KCCM41747), Salmonella enterica subsp.enterica (KCCM11806), Listeria monocytogenes (KCCM40307). Fungi (including fungi): Cryptococcus neoformans (KCCM50785), Candida albicans (KCCM11282), Aspergillus fumigatus (ATCC Mya-4609), Aspergillus niger (KCCM60332), Fusarium oxysporum (KCCM44187), Penicillium chrysogenum (KCCM60353) and Malassezia furfur (KCCM12679). Next, each colony of the pathogen was inoculated into a nutrient broth medium and incubated for 24 hours at an appropriate temperature (37°C for E coli, Staphylococcus aureus and Bacillus; 30°C for Cryptococcus and Candida), followed by the addition of 20% glycerol, and then stored at -80°C cryogenic freezer. In the case of Aspergillus, Fusarium and Penicillium, the spores were harvested with PBS (phosphate buffer saline) from YPD medium (Sigma-Aldrich) after 7 days incubation at 30°C, followed by the addition of 20% glycerol, and then stored at -80°C, cryogenic freezer. [Table 3] Pathogenic Microorganisms Nutrient media E. coli LB (Luria Bertani)Staphylococcus aureus TSB (Tryptic Soy Broth)Bacillus cereus NB (Nutrient Broth)Cryptococcus neoformans YM (Yeast Mold)Candida albicans YM (Yeast Mold)Aspergillus fumigatus YPD (Yeast Extract, Peptone, Dextrose)Aspergillus niger PDA (Potato Dextrose Agar)Fusarium oxysporum PDA (Potato Dextrose Agar)Penicillium chrysogenum PDA (Potato Dextrose Agar) Example 2: Detection of antimicrobial and antifungal activities
    [0025] For the isolated strains, their antimicrobial and antifungal activities were detected. First, each isolated strain stored at -80°C was inoculated onto MRS solid medium and incubated at 37°C for 24 hours, and then the respective colonies were taken and suspended in 500 µℓ of PBS to prepare a sample solution for subsequent antibacterial and antifungal activity experiments. Next, media for antimicrobial and antifungal activity tests of the isolation strains were prepared. To this end, the bacteria and fungi cultured and stored in Example 1 were inoculated into a nutrient media suitable for each growth and incubated for 24 hours. Next, the soft agar medium containing MRS (1%, w/w) was sterilized at 121°C for 15 minutes, cooled to 55°C, and each culture medium including bacteria or fungi obtained above was inoculated with 1% (v/v) on the said MRS medium. The soft agar MRS medium inoculated with the bacteria or fungi was then poured into a disposable petri dish and placed at room temperature to prepare an overlay medium for antibacterial or antifungal activity experiments. A sterilized 8 mm paper disk (Adventec, 51020693) was placed on the obtained overlay medium, 50 µℓ of the isolated lactic acid bacteria or cell-free culture supernatant of the present invention was added, and incubated at the appropriate growth temperature of each bacteria or fungi for 24 hours. After the culture was completed, the diameter of the clear zone for the pathogens was measured to determine the antibacterial activity and antifungal activity of the isolated lactic acid bacteria. The antibacterial activity and antifungal activity above was indicated according to the diameter of the clear zone as follows: 8 mm or more: +, 13 mm or more: + +, 15 mm or more: + + +, 17 mm or more: + + + +. Example 3: Acid resistance and bile resistance of the lactic acid bacteria of the present invention
    [0026] The isolated lactic acid bacteria strains were cultured in Lactobacilli MRS broth for more than 16 hours and then the 100 µℓ of the bacterial culture was inoculated into 100 µℓ of MRS broth with different pH conditions (pH7.0, pH2.5) in a 96 well plate, followed by incubation at 37°C for 24 hours. The survival rate of the lactic acid bacteria was measured by comparing the absorbances of the pH7.0 culture medium and the pH2.5 culture medium at 620 nm using Microplate reader. The cell viability for the acid resistance test was measured in the following manner. Viability% = OD 24 h , pH 2.5 / OD 24h , pH 7.0 × 100
    [0027] To confirm bile resistance, the isolated lactic acid bacteria strain was cultured in Lactobacilli MRS broth for more than 16 hours and then 100 µℓ of the bacterial culture was inoculated into 100 µℓ of MRS broth with two conditions (MRS broth, MRS broth + 0.3% oxgall) in a 96 well plate, followed by incubation at 37°C for 24 hours. The survival rate was measured by comparing the absorbance at 620 nm using Microplate reader. The cell viability for the bile resistance test was measured in the following manner. Viability Measurement% = OD 24 h , MRS + 0.3 % Oxgall / OD 24 h , MRS × 100
    [0028] The acid resistance and bile resistance of the novel lactic acid bacteria of the present invention were 86.87% and 99.37%, respectively, and were found to have excellent properties exceeding the general standard of 70%. Example 4: Expression of TJ (tight junction) proteins in Caco-2 cells or HaCaT cells by the lactic acid bacteria of the present invention
    [0029] The induction of expression of the intestinal TJ constituent proteins was confirmed by using Caco-2 cells (obtained from Korean Cell Line bank), intestinal epithelial cells. As shown in FIG.6, it was confirmed that the cell-free supernatant of the lactic acid bacteria of the present invention effectively induced the expression of ZO-1, Occludin, Claudin-1 and Claudin-4 proteins. Next, HaCaT cells (obtained from Korean Cell Line Bank) were used to confirm the induction of expression of TJ constituent proteins. As a result, as shown in FIG.7, it was confirmed that the said cell-free supernatant of the present invention effectively induced the expression of ZO-1 ATP, Occludin, Claudin-1, and Claudin-4 proteins in the HaCaT cells. Specifically, the freeze-dried powder of the said cell-free culture supernatant was first quantified and dissolved in PBS. To prevent microbial contamination, 0.2 µm syringe filtration was performed and treated at a concentration suitable for 6 well plate. The cell lysis was then performed using a RIPA/PI buffer, after 24 hours of incubation in a 37°C, CO2 incubator. The protein was quantified via Bradford assay, and then SDS-PAGE was carried out. SDS-PAGE was loaded with 20 µg per lane, and performed at 150 V for 1 h 30 min running, at 100 V for 1 h transfer (NC membrane) followed by blocking for 1 h (4% SKIM milk). Then, Claudin-1 (1:1000) as a primary antibody was treated for 16 hours and beta-actin (1:1000) was treated for 1 hour. As a secondary antibody, Claudin-1(anti-rabbit, 1:2000) was treated for 1 hour and beta-actin (anti-mouse, 1:2000) was treated for one hour. The band was detected using ECL kit. Example 5: Antimicrobial activity test of the lactic acid bacterial culture supernatant of the present invention (MIC, Minimum Inhibitory Concentration)
    [0030] The minimum inhibitory concentration (MIC) measurement was performed by a standard test method (Wiegand et al. Nat Protoc. 2008). First, E. coli, S. aureus or B. cereus was inoculated onto a sterile test solid nutrient medium (MHB, Muller Histone Broth, Difco) and cultured. The C. neoformans or C. albicans was inoculated on YM nutrient medium (Difco) and A. fumigatus was inoculated on YPD nutrient medium (Difco), and incubated at 37°C for 24 hours. The bacteria were then inoculated into sterile liquid medium (MHB) and the fungus was inoculated into RPMI1640 medium, respectively. Next, the cell-free bacterial culture supernatant of the present invention was added to MHB or RPMI1640 medium obtained above and incubated at 37°C for 24 hours to measure the turbidity of the pathogenic microorganisms.
    [0031] The cell-free culture supernatant solution was prepared by dissolving the freeze-dried lactic acid bacteria culture supernatant in the triple distilled water. The serial 2 x dilution of the supernatant solution said was used to confirm the lowest concentration of the culture supernatant inhibiting the visible growth of pathogens. To confirm the antibacterial and antifungal activities, the test above was repeated three times, and the OD (620 nm) value of the culture supernatant was detected using microplate spectrophotometer (Multiskan FC A28696). As shown in Table 4, the lactic acid bacteria culture supernatant of the present invention exhibited extensive inhibitory activity against Gram-positive and Gram-negative bacteria and fungi. Example 6: Antifungal activity test of the lactic acid bacterial culture supernatant of the present invention (MIC)
    [0032] Antifungal activity and MIC test were performed according to the standard test method (CLSI document M38-A2, 2008). The culture supernatant prepared in the example above was serially 2 x diluted for this experiment. Each well of each 96 well was inoculated with mold or fungi spores at a concentration of 2 × 103 spores/mℓ. The plate was incubated at 35°C for 48 hours. The MIC was determined by microscopic observation to the lowest concentration of the cell-free culture supernatant inhibiting the visible growth of the fungi or mold. The experiment was repeated three times to confirm the antifungal activity. Table 4 shows the results. [Table 4] MIC (mg/mℓ) Escherichia coli 0.7Staphylococcus aureus 0.9Staphylococcus epidermidis 1.6Propioni bacterium acnes 0.8Bacillus cereus 0.7Pseudomonas aeruginosa 0.8Salmonella 0.8Listeria 0.8Cryptococus neoformans 25 ∼ 50Candida albicans 25 ∼ 50Aspergillus niger 25 ∼ 50Fusarium oxysporum 25 ∼ 50Penicillium chrysogenum 25 ∼ 50Malassezia furfur 25 ∼ 50 Example 7: Thermal stability
    [0033] Experiments were conducted to determine whether the antibacterial and antifungal activity against the pathogens by the cell-free culture supernatant of the lactic acid bacteria has thermal stability. The concentrated culture supernatant dissolved solution was prepared in the same manner as in the above example and was divided to two groups of non-heat treatment and heat treatment to determine the MIC showing antibacterial and antifungal activities. For the heat-treated group, the culture supernatant solution was heat-treated in 80°C water bath (Biofree, BF60AC) for 30 minutes or in 121°C autoclave for 15 minutes. The results of the experiments are shown in Table 5. [Table 5] pathogens Minimum Inhibitory Concentration (mg/mℓ) non-heat treatment 80°C, 30 min. 121°C, 15 min. G (-) E. coli 0.7 0.7 0.7 G (+) S. aureus 0.9 0.9 0.9 G (+) B. cereus 0.7 0.7 0.7 fungi C. neoformans 6.25 6.25 6.25 fungi C. albicans 25.00 25.00 25.00 Example 8: pH stability
    [0034] Experiments were conducted to determine whether the antibacterial and antifungal activity against pathogens of the lactic acid bacteria culture supernatant has pH stability. The concentrated culture supernatant solution prepared in the same manner as in the above example was treated with non-pH adjusted group or pH adjusted group to measure the MIC showing antibacterial and antifungal activities.
    [0035] The pH was adjusted using lactic acids and NaHCO3. The results of the experiments are shown in Table 6 below. [Table 6] pathogens Minimum Inhibitory Concentration (mg/mℓ) non-adjusted (pH4.3) adjusted (pH4.3→7→4.5) adjusted (pH4.3→7→pH5) G (-) E. coli 0.7 0.7 0.7 G (+) S. aureus 0.9 0.9 0.9 G (+) B. cereus 0.7 0.7 0.7 fungi C. neoformans 6.25 6.25 6.25 fungi C. albicans 25.00 25.00 25.00 Example 9: Selective inhibition activity of the cell-free culture supernatant of the lactic acid bacteria
    [0036] The Pediococcus pentosaceus AB 160011 of the present invention, Lactobacillus brevis and E. coli were cultured until OD600 reached 0.8, respectively. Then, 0.5, 1 and 1.5 mℓ of Pediococcus pentosaceus AB 160011, 1 mℓ. of Lactobacillus brevis and 1 mℓ. of E. coli were used to remove the supernatant using centrifuge, and the precipitated cells were pooled and washed with distilled water (DW). After performing centrifugation again, the supernatant was removed and Pediococcus pentosaceus AB160011 was pooled in 5 µℓ of DW, and each Lactobacillus brevis and E. coli were pooled in 1 mℓ of DW. Then, each Lactobacillus brevis and Escherichia coli, which were pooled in 1 mℓ of DW, were spread evenly in the MRS solid media. Then, Pediococcus pentosaceus AB 1600115, which was pooled in 5 µℓ of DW, was spotted on the MRS medium above where Lactobacillus brevis or Escherichia coli, was spread, at a constant distance. The results were confirmed after 6 ∼ 20 hours of incubation and are shown in FIG.8. Example 10: Inflammation induction of the cell-free culture supernatant of the lactic acid bacteria
    [0037] The amount of Nitric Oxide, an inflammatory response indicator, was measured. First, RAW264.7 cells were seeded in 12 well plates with 1 × 105 cells per well and were incubated overnight. The 0.2 g of the lyophilized sample of the cell-free culture supernatant of Pediococcus pentosaceus AB160011 was dissolved in 1 mℓ of DMEM. The RAW264.7 cells were treated with 0.25, 0.3, 0.35, 0.4, 0.45 and 0.5% (wt/v) of the cell-free culture supernatant dissolved in DMEM above, and incubated for 24 hours. The amount of NO was determined by measuring the absorbance at 540 nm using Nitric Oxide Colorimetric Assay kit (BioVision). As a result, the said culture supernatant of the present invention did not induce an inflammatory response. The results are shown in FIG.9.
    [0038] RAW R264.7 cells were seeded into 12 well plates at a concentration of 1 × 105 cells per well. One day after the seeding, each well was treated with Pediococcus pentosaceus AB 160011 at each concentration of 5 × 107, 1 × 108 and 2 × 108 CFU/mℓ for 2 hours and then the amount of NO was measured at 540 nm using Nitric Oxide Colorimetric Assay kit (Biovision, Korea). As a result, the lactic acid bacteria of the present invention did not induce an inflammatory response. The results are shown in FIG. 10. Example 11: Anti-inflammatory effect of lactic acid bacteria of the present invention
    [0039] One day after the seed inoculation of 1 × 105 cells per well in a 12 well plate of RAW R264.7 cells, 1 × 108 or 2 × 108 cfu/mℓ of Pediococcus pentosaceus AB 160011 were added to each well, and each well was treated with 1 µg/mℓ of LPS for 24 hours to induce inflammation.
    [0040] The amount of NO was determined at 540 nm using Nitric Oxide Colorimetric Assay kit (Biovision, Korea). As a result, the lactic acid bacteria of the present invention have been shown to inhibit inflammation reactions. The results are shown in FIG.11. Example 12: Measurement of antioxidant effect
    [0041] The DPPH (1,1-diphenyl-2-picrylhydrazyl), which is a water-soluble material having a chemically stabilized free radical, has a maximum absorbance between 515 nm and 520 nm, and the radical (DPPH) is extinguished and discolored when the material encounters a material having an antioxidant activity. It is known that a chemically stable 1-diphenyl-2-picylhydryl radical (DPPH) can be used to analyze an antioxidant effects of the extracts containing several antioxidant components, a beverage, an oil, a pure phenol compound, and the like. The cell-free bacterial culture supernatant of the present invention was added to 500 mℓ of 0.2 mM
    [0042] DPPH, wherein the said culture supernatant was applied at each concentration of 0.1, 0.25, 0.3, 0.35, 0.4, 0.45 and 0.5 (wt/v)% (or 0.1, 0.25, 0.5, 0.75, 1, 1.5 and 2 (wt/v)%) while adjusting the final volume of the mixture to 1 mℓ. The absorbance was measured at 540 nm after the reaction in the dark room for 30 minutes. As a result, as shown in FIG.12, the present lactic acid bacterial culture supernatant was shown to increase the antioxidant effects in a concentration-dependent manner. Example 13: Skin irritation replacement test
    [0043] A skin irritation test using a SKINETHIC human skin model (EPISKIN) was carried out at Korea Testing & Research Institute (KTR) according to the guidelines for testing toxicology for cosmetics and animal replacement tests (V) / skin irritation test method (Ministry of Food and Drug Safety, MFDS; Guideline-0752-01). The 16 µℓ of the test article of the cell-free bacterial culture supernatant was applied to the said human skin model with 1 minute intervals per tissue and exposed for 42 minutes (± 1) in the clean bench. The test material was then removed and washed a total of 25 times with PBS (1 mℓ at one-time). The reversible damage to the said human skin model was evaluated by incubation the treated human skin at 37°C for 42 hours ± 1 hour in a 5% CO2 incubator. Each group of the three groups of the negative control, the positive control, and the test material group was set to have three repetitive samples. The cell viability of the test article was determined to be 86.3 ± 2.9% over 50% of the cell viability baseline and determined to be non-irritating to the skin. The results are shown in FIG.13. Example 14: Skin moisturizing improvement effects of a cosmetic essence containing the cell-free lactic acid bacteria culture supernatant of the present invention
    [0044] In order to evaluate the effects of improving skin moisturizing of the cosmetic essence product containing the cell-free bacterial supernatant of the present invention, a clinical test was performed at KTR (Korea). The skin moisturizing assay and abnormal response assay were performed for 22 females aged between 29 years and 59 years using Corneometer both before and after the use of the product. The results of skin moisturization have shown a statistically significant increase of the moisture content in the forehead, both cheeks and jaw areas two and four weeks after use compared to before the product was used (see FIG.14). The evaluation of adverse effects by dermatologists did not report any special skin adverse events to the test subjects during the period of use of the test article, nor did any abnormalities be observed in the scientific examination by dermatologists. Industrial Applicability
    [0045] The present invention confirms that a novel lactic acid bacterial strain isolated from soybean paste, a Korean traditional fermented food, and the cell-free bacterial culture supernatant thereof have excellent antibacterial and antifungal activities, and induce the expression of proteins involved in TJ (tight junctions) of skin and intestinal epithelial cells. In addition, the bacterial strain and the supernatant of present invention have anti-inflammatory and antioxidant effects, and have effects of enhancing skin moisturization according to clinical trials. Therefore, the lactic acid bacterial strain of the present invention could be widely used in a wide range of industrial sectors such as health functional foods, cosmetics and preservatives. (Deposit No.)
    [0046] Deposit institution name: Korean Culture Center of Microorganisms (overseas).Deposit No.: KCCM11954PDeposit Date: 20161207
    权利要求:
    Claims (5)
    [0001] A novel Pediococcus pentosacus AB160011 strain (Deposit no.: KCCM11954P).
    [0002] A health functional food for improving inflammatory bowel disease comprising the strain of claim 1.
    [0003] An antimicrobial composition comprising the cell-free culture supernatant of the strain of claim 1.
    [0004] An antifungal composition comprising the cell-free culture supernatant of the strain of claim 1.
    [0005] A cosmetic composition comprising the cell-free culture supernatant of the strain of claim 1.
    类似技术:
    公开号 | 公开日 | 专利标题
    Aguilar-Toalá et al.2017|Assessment of multifunctional activity of bioactive peptides derived from fermented milk by specific Lactobacillus plantarum strains
    Abadía-García et al.2013|Influence of probiotic strains added to cottage cheese on generation of potentially antioxidant peptides, anti-listerial activity, and survival of probiotic microorganisms in simulated gastrointestinal conditions
    Lee et al.2011|Evaluation of probiotic characteristics of newly isolated Lactobacillus spp.: immune modulation and longevity
    Endo et al.2013|Honeybees and beehives are rich sources for fructophilic lactic acid bacteria
    Fakruddin et al.2017|Antimicrobial and antioxidant activities of Saccharomyces cerevisiae IFST062013, a potential probiotic
    US10842833B2|2020-11-24|Lactobacillus plantarum and composition comprising same
    de Almeida Júnior et al.2015|Characterization and evaluation of lactic acid bacteria isolated from goat milk
    Shokryazdan et al.2014|Probiotic potential of Lactobacillus strains with antimicrobial activity against some human pathogenic strains
    Simova et al.2009|Characterization and antimicrobial spectrum of bacteriocins produced by lactic acid bacteria isolated from traditional Bulgarian dairy products
    Gomaa2013|Antimicrobial and anti-adhesive properties of biosurfactant produced by lactobacilli isolates, biofilm formation and aggregation ability
    AU2008257455B2|2014-05-01|Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
    CN101160389B|2011-04-20|Novel acid tolerant lactobacillus sakei probio- 65 with the ability of growth suppression of pathogenic microorganisms and the anti-allergic effect
    KR20170032845A|2017-03-23|Novel lactic acid bacteria and composition for preventing, improving or treating neurodegenerative diseases or cognitive dysfunction
    EP1002051B1|2011-01-26|Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom
    Dabour et al.2009|In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes
    US10272122B2|2019-04-30|Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile
    CN105087423B|2019-10-22|Novel Bei Laisi bacillus CJBV and the bactericidal composition containing it
    Soleimani et al.2010|Antagonistic activity of probiotic lactobacilli against Staphylococcus aureus isolated from bovine mastitis
    EP0760848B1|1998-02-04|Lactobacillus strains of human origin, their compositions and uses thereof
    TWI401086B|2013-07-11|Lactobacillus plantarum and uses thereof
    US7618658B2|2009-11-17|Anti-microbial agent and anti-microbial composition
    Kang et al.2009|Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect
    Nami et al.2014|Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells
    Ghanbari et al.2013|Antimicrobial activity and partial characterization of bacteriocins produced by lactobacilli isolated from Sturgeon fish
    Lee et al.2017|Probiotic characteristics of Bacillus strains isolated from Korean traditional soy sauce
    同族专利:
    公开号 | 公开日
    CN111902530A|2020-11-06|
    WO2019093611A1|2019-05-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2019-05-18| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
    2020-08-14| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-08-14| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-09-16| 17P| Request for examination filed|Effective date: 20200610 |
    2020-09-16| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-09-16| AX| Request for extension of the european patent|Extension state: BA ME |
    2021-02-17| DAV| Request for validation of the european patent (deleted)|
    2021-02-17| DAX| Request for extension of the european patent (deleted)|
    2021-08-18| A4| Supplementary search report drawn up and despatched|Effective date: 20210715 |
    2021-08-18| RIC1| Information provided on ipc code assigned before grant|Ipc: C12N1/20 20060101AFI20210709BHEP Ipc: A01N 63/20 20200101ALI20210709BHEP Ipc: A23L 33/135 20160101ALI20210709BHEP Ipc: A61K8/99 20170101ALI20210709BHEP Ipc: A61Q 19/00 20060101ALI20210709BHEP Ipc: C12R1/01 20060101ALI20210709BHEP |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]